{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T16:02:54Z","timestamp":1771603374989,"version":"3.50.1"},"reference-count":144,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Tampere University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-12634-x","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T17:47:47Z","timestamp":1769708867000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nucleocapsid protein enhances spike- and RBD-specific humoral and cellular immune responses in protein-based SARS-CoV-2 vaccine"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3772-7233","authenticated-orcid":false,"given":"Stina","family":"Gr\u00f6hn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3187-0663","authenticated-orcid":false,"given":"Heini","family":"Lehto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3546-4572","authenticated-orcid":false,"given":"Saana","family":"Soppela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7473-0637","authenticated-orcid":false,"given":"Rauno A.","family":"Naves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1384-5629","authenticated-orcid":false,"given":"Mikael A.","family":"Ritvos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3373-1753","authenticated-orcid":false,"given":"Alina","family":"Iakubovskaia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2153-6149","authenticated-orcid":false,"given":"Vili","family":"Lampinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4478-1773","authenticated-orcid":false,"given":"Iiris","family":"Mustonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanniina","family":"Pakkala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizaveta","family":"Husu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9271-4059","authenticated-orcid":false,"given":"Laura","family":"Kakkola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0165-2564","authenticated-orcid":false,"given":"Ilkka","family":"Julkunen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5997-8167","authenticated-orcid":false,"given":"Pekka","family":"Kolehmainen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6088-4245","authenticated-orcid":false,"given":"Arja","family":"Pasternack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7017-6931","authenticated-orcid":false,"given":"Olli","family":"Ritvos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6463-1248","authenticated-orcid":false,"given":"Minna M.","family":"Hankaniemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"12634_CR1","first-page":"986","volume-title":"Fields virology: emerging viruses","author":"S Perlman","year":"2020","unstructured":"Perlman S, Masters PS. Coronaviridae: the viruses and their replication. In: Howley PM, Knipe DM, editors. Fields virology: emerging viruses. 7th. Philadelphia, UNITED STATES: Wolters Kluwer Health; 2020 [cited 2023 Jan 12]. p. 986\u20131073. Available from: http:\/\/ebookcentral.proquest.com\/lib\/tampere\/detail.action?docID=6676894.","edition":"7th"},{"key":"12634_CR2","unstructured":"Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. [cited 2024 May 16]. Available from: https:\/\/www.who.int\/publications\/m\/item\/summary-of-probable-sars-cases-with-onset-of-illness-from-1-november-2002-to-31-july-2003."},{"issue":"7798","key":"12634_CR3","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","volume":"579","author":"F Wu","year":"2020","unstructured":"Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265\u201369.","journal-title":"Nature"},{"key":"12634_CR4","unstructured":"Coronavirus disease (COVID-19) - World Health Organization. [cited 2024 May 16]. Available from: https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019."},{"issue":"3","key":"12634_CR5","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41579-020-00459-7","volume":"19","author":"B Hu","year":"2021","unstructured":"Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19(3):141\u201354.","journal-title":"Nat Rev Microbiol"},{"issue":"2","key":"12634_CR6","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","volume":"181","author":"AC Walls","year":"2020","unstructured":"Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Structure VD. Function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181(2):281\u201392.e6.","journal-title":"Cell"},{"issue":"1","key":"12634_CR7","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12929-020-00695-2","volume":"27","author":"YD Li","year":"2020","unstructured":"Li YD, Chi WY, Su JH, Ferrall L, Hung CF, Wu TC. Coronavirus vaccine development: from SARS and MERS to COVID-19. J Biomed Sci. 2020;27(1):104.","journal-title":"J Biomed Sci"},{"issue":"9","key":"12634_CR8","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1586\/14760584.2016.1167603","volume":"15","author":"L Du","year":"2016","unstructured":"Du L, Tai W, Zhou Y, Jiang S. Vaccines for the prevention against the threat of MERS-CoV. Expert Rev Vaccines. 2016;15(9):1123\u201334.","journal-title":"Expert Rev Vaccines"},{"issue":"3","key":"12634_CR9","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nrmicro2090","volume":"7","author":"L Du","year":"2009","unstructured":"Du L, He Y, Zhou Y, Liu S, Zheng BJ, Jiang S. The spike protein of SARS-CoV - a target for vaccine and therapeutic development. Nat Rev Microbiol. 2009;7(3):226\u201336.","journal-title":"Nat Rev Microbiol"},{"key":"12634_CR10","doi-asserted-by":"publisher","first-page":"298","DOI":"10.3389\/fmicb.2020.00298","volume":"11","author":"N Wang","year":"2020","unstructured":"Wang N, Shang J, Jiang S, Du L. Subunit vaccines against emerging pathogenic human coronaviruses. Front Microbiol. 2020;11:298.","journal-title":"Front Microbiol"},{"issue":"8","key":"12634_CR11","doi-asserted-by":"publisher","first-page":"3718","DOI":"10.1128\/JCM.43.8.3718-3726.2005","volume":"43","author":"YX He","year":"2005","unstructured":"He YX, Zhou YS, Siddiqui P, Niu JK, Jiang SB. Identification of immunodominant epitopes on the membrane protein of the severe acute respiratory syndrome-associated coronavirus. J Clin Microbiol. 2005;43(8):3718\u201326.","journal-title":"J Clin Microbiol"},{"issue":"36","key":"12634_CR12","doi-asserted-by":"publisher","first-page":"5001","DOI":"10.1016\/j.vaccine.2009.05.073","volume":"27","author":"N Zheng","year":"2009","unstructured":"Zheng N, Xia R, Yang C, Yin B, Li Y, Duan C, et al. Boosted expression of the SARS-CoV nucleocapsid protein in tobacco and its immunogenicity in mice. Vaccine. 2009;27(36):5001\u201307.","journal-title":"Vaccine"},{"issue":"16","key":"12634_CR13","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1016\/j.vaccine.2006.01.058","volume":"24","author":"SJ Liu","year":"2006","unstructured":"Liu SJ, Leng CH, Lien SP, Chi HY, Huang CY, Lin CL, et al. Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates. Vaccine. 2006;24(16):3100\u201308.","journal-title":"Vaccine"},{"key":"12634_CR14","unstructured":"WHO. COVID-19 vaccine tracker and landscape. [cited 2025 Apr 17]. Available from: https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines."},{"key":"12634_CR15","unstructured":"COVID-19 medicines | European Medicines Agency (EMA). [cited 2025 Apr 24]. Available from: https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/public-health-threats\/coronavirus-disease-covid-19\/covid-19-medicines."},{"key":"12634_CR16","unstructured":"Comirnaty | European Medicines Agency (EMA). 2020 [cited 2025 Apr 24]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/comirnaty."},{"key":"12634_CR17","unstructured":"Kostaive | European Medicines Agency (EMA). 2025 [cited 2025 Apr 24]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/kostaive."},{"key":"12634_CR18","unstructured":"Nuvaxovid | European Medicines Agency (EMA). 2021 [cited 2025 Apr 24]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/nuvaxovid."},{"key":"12634_CR19","unstructured":"Spikevax (previously COVID-19 Vaccine Moderna) | European Medicines Agency (EMA). 2021 [cited 2025 Apr 24]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/spikevax."},{"issue":"10","key":"12634_CR20","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/s41577-020-00434-6","volume":"20","author":"M Jeyanathan","year":"2020","unstructured":"Jeyanathan M, Afkhami S, Smaill F, Miller MS, Lichty BD, Xing Z. Immunological considerations for COVID-19 vaccine strategies. Nat Rev Immunol. 2020;20(10):615\u201332.","journal-title":"Nat Rev Immunol"},{"issue":"76","key":"12634_CR21","doi-asserted-by":"publisher","first-page":"eadd 4853","DOI":"10.1126\/sciimmunol.add4853","volume":"7","author":"J Tang","year":"2022","unstructured":"Tang J, Zeng C, Cox TM, Li C, Son YM, Cheon IS, et al. Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination. Sci Immunol. 2022;7(76):eadd4853.","journal-title":"Sci Immunol"},{"issue":"6553","key":"12634_CR22","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1126\/science.abg9857","volume":"373","author":"FE Lund","year":"2021","unstructured":"Lund FE, Randall TD. Scent of a vaccine. Science. 2021;373(6553):397\u201399.","journal-title":"Science"},{"issue":"34","key":"12634_CR23","doi-asserted-by":"publisher","first-page":"eaas 9673","DOI":"10.1126\/sciimmunol.aas9673","volume":"4","author":"PA Szabo","year":"2019","unstructured":"Szabo PA, Miron M, Farber DL. Location, location, location: tissue resident memory T cells in mice and humans. Sci Immunol. 2019;4(34):eaas9673.","journal-title":"Sci Immunol"},{"issue":"1","key":"12634_CR24","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41590-018-0260-6","volume":"20","author":"SR Allie","year":"2019","unstructured":"Allie SR, Bradley JE, Mudunuru U, Schultz MD, Graf BA, Lund FE, et al. The establishment of resident memory B cells in the lung requires local antigen encounter. Nat Immunol. 2019;20(1):97\u2013108.","journal-title":"Nat Immunol"},{"issue":"4","key":"12634_CR25","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.immuni.2020.07.019","volume":"53","author":"D Laczk\u00f3","year":"2020","unstructured":"Laczk\u00f3 D, Hogan MJ, Toulmin SA, Hicks P, Lederer K, Gaudette BT, et al. A single immunization with nucleoside-modified mRNA vaccines elicits strong cellular and humoral immune responses against SARS-CoV-2 in mice. Immunity. 2020;53(4):724\u201332.e7.","journal-title":"Immunity"},{"key":"12634_CR26","doi-asserted-by":"crossref","unstructured":"Goel RR, Painter MM, Apostolidis SA, Mathew D, Meng W, Rosenfeld AM, et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science. 2021;374(6572):abm0829.","DOI":"10.1126\/science.abm0829"},{"issue":"7870","key":"12634_CR27","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41586-021-03738-2","volume":"596","author":"JS Turner","year":"2021","unstructured":"Turner JS, O\u2019Halloran JA, Kalaidina E, Kim W, Schmitz AJ, Zhou JQ, et al. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature. 2021;596(7870):109\u201313.","journal-title":"Nature"},{"issue":"64","key":"12634_CR28","doi-asserted-by":"publisher","first-page":"eabl 4509","DOI":"10.1126\/sciimmunol.abl4509","volume":"6","author":"B Israelow","year":"2021","unstructured":"Israelow B, Mao T, Klein J, Song E, Menasche B, Omer SB, et al. Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2. Sci Immunol. 2021;6(64):eabl4509.","journal-title":"Sci Immunol"},{"issue":"5","key":"12634_CR29","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41385-022-00511-0","volume":"15","author":"S Sheikh-Mohamed","year":"2022","unstructured":"Sheikh-Mohamed S, Isho B, Chao GYC, Zuo M, Cohen C, Lustig Y, et al. Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection. Mucosal Immunol. 2022;15(5):799\u2013808.","journal-title":"Mucosal Immunol"},{"issue":"1","key":"12634_CR30","doi-asserted-by":"publisher","first-page":"5135","DOI":"10.1038\/s41467-022-32389-8","volume":"13","author":"K Sano","year":"2022","unstructured":"Sano K, Bhavsar D, Singh G, Floda D, Srivastava K, Gleason C, et al. SARS-CoV-2 vaccination induces mucosal antibody responses in previously infected individuals. Nat Commun. 2022;13(1):5135.","journal-title":"Nat Commun"},{"issue":"1","key":"12634_CR31","doi-asserted-by":"publisher","first-page":"7114","DOI":"10.1038\/s41467-023-42796-0","volume":"14","author":"W Li","year":"2023","unstructured":"Li W, Wang T, Rajendrakumar AM, Acharya G, Miao Z, Varghese BP, et al. An FcRn-targeted mucosal vaccine against SARS-CoV-2 infection and transmission. Nat Commun. 2023;14(1):7114.","journal-title":"Nat Commun"},{"issue":"6622","key":"12634_CR32","doi-asserted-by":"publisher","first-page":"eabo 2523","DOI":"10.1126\/science.abo2523","volume":"378","author":"T Mao","year":"2022","unstructured":"Mao T, Israelow B, Pe\u00f1a-Hern\u00e1ndez MA, Suberi A, Zhou L, Luyten S, et al. Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses. Science. 2022;378(6622):eabo2523.","journal-title":"Science"},{"issue":"1","key":"12634_CR33","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1080\/22221751.2022.2097479","volume":"11","author":"X Li","year":"2022","unstructured":"Li X, Wang L, Liu J, Fang E, Liu X, Peng Q, et al. Combining intramuscular and intranasal homologous prime-boost with a chimpanzee adenovirus-based COVID-19 vaccine elicits potent humoral and cellular immune responses in mice. Emerg Microbes Infect. 2022;11(1):1890\u201399.","journal-title":"Emerg Microbes Infect"},{"issue":"1","key":"12634_CR34","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.cell.2020.08.026","volume":"183","author":"AO Hassan","year":"2020","unstructured":"Hassan AO, Kafai NM, Dmitriev IP, Fox JM, Smith BK, Harvey IB, et al. A single-dose intranasal ChAd vaccine protects Upper and lower respiratory tracts against SARS-CoV-2. Cell. 2020;183(1):169\u201384.e13.","journal-title":"Cell"},{"issue":"4","key":"12634_CR35","doi-asserted-by":"publisher","first-page":"100230","DOI":"10.1016\/j.xcrm.2021.100230","volume":"2","author":"AO Hassan","year":"2021","unstructured":"Hassan AO, Feldmann F, Zhao H, Curiel DT, Okumura A, Tang-Huau TL, et al. A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques. Cell Rep Med. 2021;2(4):100230.","journal-title":"Cell Rep Med"},{"issue":"3","key":"12634_CR36","doi-asserted-by":"publisher","first-page":"109400","DOI":"10.1016\/j.celrep.2021.109400","volume":"36","author":"TL Bricker","year":"2021","unstructured":"Bricker TL, Darling TL, Hassan AO, Harastani HH, Soung A, Jiang X, et al. A single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters. Cell Rep. 2021;36(3):109400.","journal-title":"Cell Rep"},{"issue":"1","key":"12634_CR37","doi-asserted-by":"publisher","first-page":"5868","DOI":"10.1038\/s41467-021-26178-y","volume":"12","author":"RJ Fischer","year":"2021","unstructured":"Fischer RJ, van Doremalen N, Adney DR, Yinda CK, Port JR, Holbrook MG, et al. ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7. Nat Commun. 2021;12(1):5868.","journal-title":"Nat Commun"},{"issue":"607","key":"12634_CR38","doi-asserted-by":"publisher","first-page":"eabh 0755","DOI":"10.1126\/scitranslmed.abh0755","volume":"13","author":"N van Doremalen","year":"2021","unstructured":"van Doremalen N, Purushotham JN, Schulz JE, Holbrook MG, Bushmaker T, Carmody A, et al. Intranasal ChAdOx1 nCoV-19\/azd1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models. Sci Transl Med. 2021;13(607):eabh0755.","journal-title":"Sci Transl Med"},{"key":"12634_CR39","doi-asserted-by":"publisher","first-page":"1514845","DOI":"10.3389\/fimmu.2025.1514845","volume":"16","author":"Y Sui","year":"2025","unstructured":"Sui Y, Kar S, Chawla B, Hoang T, Yu Y, Wallace SM, et al. Adjuvanted subunit intranasal vaccine reduces SARS-CoV-2 onward transmission in hamsters. Front Immunol. 2025;16:1514845.","journal-title":"Front Immunol"},{"issue":"7","key":"12634_CR40","doi-asserted-by":"publisher","first-page":"795","DOI":"10.3390\/vaccines12070795","volume":"12","author":"J Tobias","year":"2024","unstructured":"Tobias J, Steinberger P, Wilkinson J, Klais G, Kundi M, Wiedermann U. SARS-CoV-2 vaccines: the advantage of mucosal vaccine delivery and local immunity. Vaccines. 2024;12(7):795.","journal-title":"Vaccines"},{"issue":"1","key":"12634_CR41","doi-asserted-by":"publisher","first-page":"2368288","DOI":"10.1080\/21645515.2024.2368288","volume":"20","author":"SC Park","year":"2024","unstructured":"Park SC, Wiest MJ, Yan V, Wong PT, Schotsaert M. Induction of protective immune responses at respiratory mucosal sites. Hum Vaccines Immunother. 2024;20(1):2368288.","journal-title":"Hum Vaccines Immunother"},{"issue":"2","key":"12634_CR42","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1084\/jem.189.2.371","volume":"189","author":"A Regnault","year":"1999","unstructured":"Regnault A, Lankar D, Lacabanne V, Rodriguez A, Th\u00e9ry C, Rescigno M, et al. Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med. 1999;189(2):371\u201380.","journal-title":"J Exp Med"},{"key":"12634_CR43","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1146\/annurev.immunol.19.1.275","volume":"19","author":"JV Ravetch","year":"2001","unstructured":"Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol. 2001;19:275\u201390.","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"12634_CR44","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/nri2206","volume":"8","author":"F Nimmerjahn","year":"2008","unstructured":"Nimmerjahn F, Ravetch JV. Fc\u03b3 receptors as regulators of immune responses. Nat Rev Immunol. 2008;8(1):34\u201347.","journal-title":"Nat Rev Immunol"},{"key":"12634_CR45","doi-asserted-by":"crossref","unstructured":"Junker F, Gordon J, Qureshi O. Fc gamma receptors and their Role in antigen uptake, presentation, and T cell activation. Front Immunol. 2020;11. https:\/\/www.frontiersin.orghttps:\/\/www.frontiersin.org\/journals\/immunology\/articles\/10.3389\/fimmu.2020.01393\/full.","DOI":"10.3389\/fimmu.2020.01393"},{"issue":"3","key":"12634_CR46","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1084\/jem.20020400","volume":"196","author":"GM Spiekermann","year":"2002","unstructured":"Spiekermann GM, Finn PW, Ward ES, Dumont J, Dickinson BL, Blumberg RS, et al. Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: functional expression of FcRn in the mammalian lung. J Exp Med. 2002;196(3):303\u201310.","journal-title":"J Exp Med"},{"issue":"7212","key":"12634_CR47","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/nature07255","volume":"455","author":"W He","year":"2008","unstructured":"He W, Ladinsky MS, Huey-Tubman KE, Jensen GJ, McIntosh JR, Bj\u00f6rkman PJ. FcRn-mediated antibody transport across epithelial cells revealed by electron tomography. Nature. 2008;455(7212):542\u201346.","journal-title":"Nature"},{"issue":"9","key":"12634_CR48","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/nri2155","volume":"7","author":"DC Roopenian","year":"2007","unstructured":"Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7(9):715\u201325.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"12634_CR49","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1093\/intimm\/dxg018","volume":"15","author":"ES Ward","year":"2003","unstructured":"Ward ES, Zhou J, Ghetie V, Ober RJ. Evidence to support the cellular mechanism involved in serum IgG homeostasis in humans. Int Immunol. 2003;15(2):187\u201395.","journal-title":"Int Immunol"},{"issue":"1","key":"12634_CR50","doi-asserted-by":"publisher","first-page":"50","DOI":"10.7774\/cevr.2012.1.1.50","volume":"1","author":"JH Rhee","year":"2012","unstructured":"Rhee JH, Lee SE, Kim SY. Mucosal vaccine adjuvants update. Clin Exp Vaccine Res. 2012;1(1):50\u201363.","journal-title":"Clin Exp Vaccine Res"},{"issue":"2","key":"12634_CR51","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.cell.2020.09.040","volume":"183","author":"A Iwasaki","year":"2020","unstructured":"Iwasaki A, Omer SB. Why and how vaccines work. Cell. 2020;183(2):290\u201395.","journal-title":"Cell"},{"issue":"2","key":"12634_CR52","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/imm.13526","volume":"167","author":"VA Correa","year":"2022","unstructured":"Correa VA, Portilho AI, De Gaspari E. Vaccines, adjuvants and key factors for mucosal immune response. Immunology. 2022;167(2):124\u201338.","journal-title":"Immunology"},{"key":"12634_CR53","doi-asserted-by":"publisher","first-page":"113380","DOI":"10.1016\/j.jim.2022.113380","volume":"511","author":"LP Deimel","year":"2022","unstructured":"Norton EB, Lawson LB, Freytag LC, Clements JD. Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G\/L211A), as a safe and effective oral adjuvant. Clin Vaccine Immunol. 2011;18(4):546\u201351.","journal-title":"J Immunol Methods"},{"issue":"9","key":"12634_CR54","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/nbt.2344","volume":"30","author":"F Wegmann","year":"2012","unstructured":"Lebens M, Terrinoni M, Karlsson SL, Larena M, Gustafsson-Hedberg T, K\u00e4llg\u00e5rd S, et al. Construction and preclinical evaluation of mmCT, a novel mutant cholera toxin adjuvant that can be efficiently produced in genetically manipulated Vibrio cholerae. Vaccine. 2016;34(18):2121\u20138.","journal-title":"Nat Biotechnol"},{"key":"12634_CR55","doi-asserted-by":"publisher","first-page":"1078904","DOI":"10.3389\/fimmu.2022.1078904","volume":"13","author":"JL Molina Estupi\u00f1an","year":"2023","unstructured":"Molina Estupi\u00f1an JL, Aradottir Pind AA, Foroutan Pajoohian P, Jonsdottir I, Bjarnarson SP. The adjuvants dmLT and mmCT enhance humoral immune responses to a pneumococcal conjugate vaccine after both parenteral or mucosal immunization of neonatal mice. Front Immunol. 2023;13:1078904.","journal-title":"Front Immunol"},{"issue":"18","key":"12634_CR56","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1016\/j.vaccine.2014.02.004","volume":"32","author":"C Ma","year":"2014","unstructured":"Ma C, Li Y, Wang L, Zhao G, Tao X, Tseng CTK, et al. Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: implication for designing novel mucosal MERS vaccines. Vaccine. 2014;32(18):2100\u201308.","journal-title":"Vaccine"},{"issue":"9","key":"12634_CR57","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1007\/s00253-023-12490-8","volume":"107","author":"CJ Li","year":"2023","unstructured":"Li CJ, Jiang CL, Chao TL, Lin SY, Tsai YM, Chao CS, et al. Elicitation of potent neutralizing antibodies in obese mice by ISA 51-adjuvanted SARS-CoV-2 spike RBD-Fc vaccine. Appl Microbiol Biotechnol. 2023;107(9):2983\u201395.","journal-title":"Appl Microbiol Biotechnol"},{"issue":"16","key":"12634_CR58","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1016\/j.vaccine.2021.03.006","volume":"39","author":"Y Du","year":"2021","unstructured":"Du Y, Xu Y, Feng J, Hu L, Zhang Y, Zhang B, et al. Intranasal administration of a recombinant RBD vaccine induced protective immunity against SARS-CoV-2 in mouse. Vaccine. 2021;39(16):2280\u201387.","journal-title":"Vaccine"},{"issue":"2","key":"12634_CR59","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.vaccine.2011.10.094","volume":"30","author":"LR Stanberry","year":"2012","unstructured":"Stanberry LR, Simon JK, Johnson C, Robinson PL, Morry J, Flack MR, et al. Safety and immunogenicity of a novel nanoemulsion mucosal adjuvant W805EC combined with approved seasonal influenza antigens. Vaccine. 2012;30(2):307\u201316.","journal-title":"Vaccine"},{"issue":"6510","key":"12634_CR60","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1126\/science.abd0826","volume":"369","author":"CL Hsieh","year":"2020","unstructured":"Hsieh CL, Goldsmith JA, Schaub JM, DiVenere AM, Kuo HC, Javanmardi K, et al. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science. 2020;369(6510):1501\u201305.","journal-title":"Science"},{"issue":"1","key":"12634_CR61","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1080\/22221751.2020.1821583","volume":"9","author":"T Li","year":"2020","unstructured":"Li T, Zheng Q, Yu H, Wu D, Xue W, Xiong H, et al. SARS-CoV-2 spike produced in insect cells elicits high neutralization titres in non-human primates. Emerg Microbes Infect. 2020;9(1):2076\u201390.","journal-title":"Emerg Microbes Infect"},{"issue":"2","key":"12634_CR62","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0378-1119(91)90171-7","volume":"98","author":"DC Tessier","year":"1991","unstructured":"Tessier DC, Thomas DY, Khouri HE, Laliberi\u00e9 F, Vernet T. Enhanced secretion from insect cells of a foreign protein fused to the honeybee melittin signal peptide. Gene. 1991;98(2):177\u201383.","journal-title":"Gene"},{"issue":"1","key":"12634_CR63","doi-asserted-by":"publisher","first-page":"10198","DOI":"10.1038\/s41598-025-94656-0","volume":"15","author":"S Soppela","year":"2025","unstructured":"Soppela S, Plavec Z, Gr\u00f6hn S, Mustonen I, Jartti M, Oikarinen S, et al. Immunological and structural evaluation of the intranasally administrated CVB1 whole-virus and VLP vaccines. Sci Rep. 2025;15(1):10198.","journal-title":"Sci Rep"},{"issue":"2","key":"12634_CR64","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1093\/infdis\/jiab222","volume":"224","author":"P Jalkanen","year":"2021","unstructured":"Jalkanen P, Pasternack A, Maljanen S, Mel\u00e9n K, Kolehmainen P, Huttunen M, et al. A combination of N and S antigens with IgA and IgG measurement strengthens the accuracy of SARS-CoV-2 Serodiagnostics. J Infect Dis. 2021;224(2):218\u201328.","journal-title":"J Infect Dis"},{"issue":"7","key":"12634_CR65","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9(7):676\u201382.","journal-title":"Nat Methods"},{"key":"12634_CR66","unstructured":"Soppela S. Production of novel engineered enterovirus-like particles. 2021 [cited 2025 Nov 26]. Available from: https:\/\/trepo.tuni.fi\/handle\/10024\/136060."},{"key":"12634_CR67","unstructured":"Lehto H. Screening optimal vaccine adjuvants for recombinant protein-based coronavirus vaccine. 2024 [cited 2025 Nov 26]. Available from: https:\/\/www.utupub.fi\/handle\/10024\/178142."},{"issue":"4","key":"12634_CR68","doi-asserted-by":"publisher","first-page":"534","DOI":"10.2144\/btn-2021-0022","volume":"71","author":"B Luckow","year":"2021","unstructured":"Luckow B, Lehmann MH. A simplified method for bronchoalveolar lavage in mice by orotracheal intubation avoiding tracheotomy. BioTechniques. 2021;71(4):534\u201337.","journal-title":"BioTechniques"},{"key":"12634_CR69","doi-asserted-by":"publisher","first-page":"1216364","DOI":"10.3389\/fcimb.2023.1216364","volume":"13","author":"V Lampinen","year":"2023","unstructured":"Lampinen V, Gr\u00f6hn S, Soppela S, Blazevic V, Hyt\u00f6nen VP, Hankaniemi MM. SpyTag\/SpyCatcher display of influenza M2e peptide on norovirus-like particle provides stronger immunization than direct genetic fusion. Front Cell Infect Microbiol. 2023;13:1216364.","journal-title":"Front Cell Infect Microbiol"},{"issue":"6483","key":"12634_CR70","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"D Wrapp","year":"2020","unstructured":"Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260\u201363.","journal-title":"Science"},{"issue":"8","key":"12634_CR71","doi-asserted-by":"publisher","first-page":"e 2954","DOI":"10.1371\/journal.pone.0002954","volume":"3","author":"PE Makidon","year":"2008","unstructured":"Makidon PE, Bielinska AU, Nigavekar SS, Janczak KW, Knowlton J, Scott AJ, et al. Pre-clinical evaluation of a novel nanoemulsion-based hepatitis B mucosal vaccine. PLoS One. 2008;3(8):e2954.","journal-title":"PLoS One"},{"key":"12634_CR72","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for industry: characterization and qualification of cell substrates and other biological materials used in the production of viral vaccines for infectious disease indications. Rockville (MD): Food and Drug Administration; 2010."},{"key":"12634_CR73","unstructured":"Cervarix | European Medicines Agency (EMA). 2018 [cited 2025 Oct 3]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cervarix."},{"issue":"9","key":"12634_CR74","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.1021\/acs.molpharmaceut.0c00372","volume":"17","author":"H Xu","year":"2020","unstructured":"Xu H, Alzhrani RF, Warnken ZN, Thakkar SG, Zeng M, Smyth HDC, et al. Immunogenicity of antigen adjuvanted with AS04 and its deposition in the upper respiratory tract after intranasal administration. Mol Pharm. 2020;17(9):3259\u201369.","journal-title":"Mol Pharm"},{"issue":"2","key":"12634_CR75","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ejpb.2004.11.011","volume":"60","author":"U Lungwitz","year":"2005","unstructured":"Lungwitz U, Breunig M, Blunk T, G\u00f6pferich A. Polyethylenimine-based non-viral gene delivery systems. Eur J Pharm Biopharm Off J Arbeitsgemeinschaft Pharm Verfahrenstech EV. 2005;60(2):247\u201366.","journal-title":"Eur J Pharm Biopharm Off J Arbeitsgemeinschaft Pharm Verfahrenstech EV"},{"issue":"3","key":"12634_CR76","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.ejpb.2010.11.007","volume":"77","author":"M G\u00fcnther","year":"2011","unstructured":"G\u00fcnther M, Lipka J, Malek A, Gutsch D, Kreyling W, Aigner A. Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung. Eur J Pharm Biopharm Off J Arbeitsgemeinschaft Pharm Verfahrenstech EV. 2011;77(3):438\u201349.","journal-title":"Eur J Pharm Biopharm Off J Arbeitsgemeinschaft Pharm Verfahrenstech EV"},{"issue":"10","key":"12634_CR77","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1093\/intimm\/dxu055","volume":"26","author":"NC Sheppard","year":"2014","unstructured":"Sheppard NC, Brinckmann SA, Gartlan KH, Puthia M, Svanborg C, Krashias G, et al. Polyethyleneimine is a potent systemic adjuvant for glycoprotein antigens. Int Immunol. 2014;26(10):531\u201338.","journal-title":"Int Immunol"},{"key":"12634_CR78","unstructured":"Coronavirus disease (COVID-19) | WHO - Prequalification of Medical products (IVDs, medicines, vaccines and immunization devices, vector control). [cited 2025 Sept 10]. Available from: https:\/\/extranet.who.int\/prequal\/vaccines\/coronavirus-disease-covid-19."},{"key":"12634_CR79","unstructured":"COVID-19 Market Dashboard | UNICEF Supply Division. [cited 2025 Sept 11]. Available from: https:\/\/www.unicef.org\/supply\/covid-19-market-dashboard."},{"issue":"1","key":"12634_CR80","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41541-024-00867-3","volume":"9","author":"RW Titball","year":"2024","unstructured":"Titball RW, Bernstein DI, Fanget NVJ, Hall RA, Longet S, MacAry PA, et al. Progress with COVID vaccine development and implementation. Npj Vaccines. 2024;9(1):69.","journal-title":"Npj Vaccines"},{"issue":"2","key":"12634_CR81","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1016\/S1473-3099(21)00472-2","volume":"22","author":"D Mostaghimi","year":"2022","unstructured":"Mostaghimi D, Valdez CN, Larson HT, Kalinich CC, Iwasaki A. Prevention of host-to-host transmission by SARS-CoV-2 vaccines. Lancet Infect Dis. 2022;22(2):e52\u20138.","journal-title":"Lancet Infect Dis"},{"issue":"7911","key":"12634_CR82","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41586-022-04690-5","volume":"605","author":"MM DeGrace","year":"2022","unstructured":"DeGrace MM, Ghedin E, Frieman MB, Krammer F, Grifoni A, Alisoltani A, et al. Defining the risk of SARS-CoV-2 variants on immune protection. Nature. 2022;605(7911):640\u201352.","journal-title":"Nature"},{"issue":"12","key":"12634_CR83","doi-asserted-by":"publisher","first-page":"5853","DOI":"10.1021\/acs.jcim.0c00501","volume":"60","author":"R Wang","year":"2020","unstructured":"Wang R, Hozumi Y, Yin C, Wei GW. Decoding SARS-CoV-2 transmission and Evolution and ramifications for COVID-19 diagnosis, vaccine, and Medicine. J Chem Inf Model. 2020;60(12):5853\u201365.","journal-title":"J Chem Inf Model"},{"issue":"2","key":"12634_CR84","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3390\/v14020187","volume":"14","author":"D Focosi","year":"2022","unstructured":"Focosi D, Maggi F, Casadevall A. Mucosal vaccines, sterilizing immunity, and the future of SARS-CoV-2 virulence. Viruses. 2022;14(2):187.","journal-title":"Viruses"},{"issue":"11","key":"12634_CR85","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1001\/jama.2021.2294","volume":"325","author":"RP Walensky","year":"2021","unstructured":"Walensky RP, Walke HT, Fauci AS. SARS-CoV-2 variants of concern in the United States-challenges and opportunities. JAMA. 2021;325(11):1037\u201338.","journal-title":"JAMA"},{"issue":"3","key":"12634_CR86","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41385-021-00467-7","volume":"15","author":"J Lange","year":"2022","unstructured":"Lange J, Rivera-Ballesteros O, Buggert M. Human mucosal tissue-resident memory T cells in health and disease. Mucosal Immunol. 2022;15(3):389\u201397.","journal-title":"Mucosal Immunol"},{"issue":"269","key":"12634_CR87","doi-asserted-by":"publisher","first-page":"269rv1","DOI":"10.1126\/scitranslmed.3010641","volume":"7","author":"RA Clark","year":"2015","unstructured":"Clark RA. Resident memory T cells in human health and disease. Sci Transl Med. 2015;7(269):269rv1.","journal-title":"Sci Transl Med"},{"key":"12634_CR88","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1038\/s41467-021-23333-3","volume":"12","author":"J Grau-Exp\u00f3sito","year":"2021","unstructured":"Grau-Exp\u00f3sito J, S\u00e1nchez-Gaona N, Massana N, Suppi M, Astorga-Gamaza A, Perea D, et al. Peripheral and lung resident memory T cell responses against SARS-CoV-2. Nat Commun. 2021;12:3010.","journal-title":"Nat Commun"},{"issue":"1","key":"12634_CR89","doi-asserted-by":"publisher","first-page":"e 1242","DOI":"10.1002\/cti2.1242","volume":"10","author":"TH Nguyen","year":"2021","unstructured":"Nguyen TH, McAuley JL, Kim Y, Zheng MZ, Gherardin NA, Godfrey DI, et al. Influenza, but not SARS-CoV-2, infection induces a rapid interferon response that wanes with age and diminished tissue-resident memory CD8+ T cells. Clin Transl Immunol. 2021;10(1):e1242.","journal-title":"Clin Transl Immunol"},{"issue":"3","key":"12634_CR90","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/s41423-022-00838-5","volume":"19","author":"SJ Choi","year":"2022","unstructured":"Choi SJ, Kim DU, Noh JY, Kim S, Park SH, Jeong HW, et al. T cell epitopes in SARS-CoV-2 proteins are substantially conserved in the omicron variant. Cell Mol Immunol. 2022;19(3):447\u201348.","journal-title":"Cell Mol Immunol"},{"issue":"4","key":"12634_CR91","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2021.01.007","volume":"184","author":"A Sette","year":"2021","unstructured":"Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021;184(4):861\u201380.","journal-title":"Cell"},{"key":"12634_CR92","doi-asserted-by":"crossref","unstructured":"Syed AM, Ciling A, Khalid MM, Sreekumar B, Chen PY, Kumar GR, et al. Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles. medRxiv. 2022, 2021.12.20.21268048.","DOI":"10.1101\/2021.12.20.21268048"},{"issue":"3","key":"12634_CR93","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/s41590-021-00870-z","volume":"22","author":"H Flament","year":"2021","unstructured":"Flament H, Rouland M, Beaudoin L, Toubal A, Bertrand L, Lebourgeois S, et al. Outcome of SARS-CoV-2 infection is linked to MAIT cell activation and cytotoxicity. Nat Immunol. 2021;22(3):322\u201335.","journal-title":"Nat Immunol"},{"issue":"51","key":"12634_CR94","doi-asserted-by":"publisher","first-page":"eabe1670","DOI":"10.1126\/sciimmunol.abe1670","volume":"5","author":"T Parrot","year":"2020","unstructured":"Parrot T, Gorin JB, Ponzetta A, Maleki KT, Kammann T, Emg\u00e5rd J, et al. MAIT cell activation and dynamics associated with COVID-19 disease severity. Sci Immunol. 2020;5(51):eabe1670.","journal-title":"Sci Immunol"},{"key":"12634_CR95","doi-asserted-by":"publisher","first-page":"11653","DOI":"10.1038\/ncomms11653","volume":"7","author":"B van Wilgenburg","year":"2016","unstructured":"van Wilgenburg B, Scherwitzl I, Hutchinson EC, Leng T, Kurioka A, Kulicke C, et al. MAIT cells are activated during human viral infections. Nat Commun. 2016;7:11653.","journal-title":"Nat Commun"},{"key":"12634_CR96","doi-asserted-by":"publisher","first-page":"101412","DOI":"10.1016\/j.coviro.2024.101412","volume":"67","author":"A Amini","year":"2024","unstructured":"Amini A, Klenerman P, Provine NM. Role of mucosal-associated invariant T cells in coronavirus disease 2019 vaccine immunogenicity. Curr Opin Virol. 2024;67:101412.","journal-title":"Curr Opin Virol"},{"issue":"13","key":"12634_CR97","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1002\/1873-3468.13488","volume":"593","author":"AM Downey","year":"2019","unstructured":"Downey AM, Kap\u0142onek P, Seeberger PH. MAIT cells as attractive vaccine targets. FEBS Lett. 2019;593(13):1627\u201340.","journal-title":"FEBS Lett"},{"issue":"9","key":"12634_CR98","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.3390\/vaccines10091538","volume":"10","author":"HY Liang","year":"2022","unstructured":"Liang HY, Wu Y, Yau V, Yin HX, Lowe S, Bentley R, et al. SARS-CoV-2 variants, current vaccines and therapeutic implications for COVID-19. Vaccines. 2022;10(9):1538.","journal-title":"Vaccines"},{"issue":"1","key":"12634_CR99","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/s41541-022-00597-4","volume":"7","author":"F Zhao","year":"2022","unstructured":"Zhao F, Zai X, Zhang Z, Xu J, Chen W. Challenges and developments in universal vaccine design against SARS-CoV-2 variants. Npj Vaccines. 2022;7(1):167.","journal-title":"Npj Vaccines"},{"issue":"13","key":"12634_CR100","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1016\/j.cell.2022.04.029","volume":"185","author":"K Xu","year":"2022","unstructured":"Xu K, Gao P, Liu S, Lu S, Lei W, Zheng T, et al. Protective prototype-beta and delta-omicron chimeric RBD-dimer vaccines against SARS-CoV-2. Cell. 2022;185(13):2265\u201378.e14.","journal-title":"Cell"},{"key":"12634_CR101","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41421-022-00383-5","volume":"8","author":"Y Liang","year":"2022","unstructured":"Liang Y, Zhang J, Yuan RY, Wang MY, He P, Su JG, et al. Design of a mutation-integrated trimeric RBD with broad protection against SARS-CoV-2. Cell Discov. 2022;8:17.","journal-title":"Cell Discov"},{"issue":"6530","key":"12634_CR102","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1126\/science.abf6840","volume":"371","author":"AA Cohen","year":"2021","unstructured":"Cohen AA, Gnanapragasam PNP, Lee YE, Hoffman PR, Ou S, Kakutani LM, et al. Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice. Science. 2021;371(6530):735\u201341.","journal-title":"Science"},{"issue":"21","key":"12634_CR103","doi-asserted-by":"publisher","first-page":"5432","DOI":"10.1016\/j.cell.2021.09.015","volume":"184","author":"AC Walls","year":"2021","unstructured":"Walls AC, Miranda MC, Sch\u00e4fer A, Pham MN, Greaney A, Arunachalam PS, et al. Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. Cell. 2021;184(21):5432\u201347.e16.","journal-title":"Cell"},{"key":"12634_CR104","doi-asserted-by":"publisher","first-page":"956","DOI":"10.3389\/fimmu.2019.00956","volume":"10","author":"MK Slifka","year":"2019","unstructured":"Slifka MK, Amanna IJ. Role of multivalency and antigenic threshold in generating protective antibody responses. Front Immunol. 2019;10:956.","journal-title":"Front Immunol"},{"issue":"15","key":"12634_CR105","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1016\/j.vaccine.2006.10.031","volume":"25","author":"L Du","year":"2007","unstructured":"Du L, Zhao G, He Y, Guo Y, Zheng BJ, Jiang S, et al. Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model. Vaccine. 2007;25(15):2832\u201338.","journal-title":"Vaccine"},{"key":"12634_CR106","unstructured":"Li Y, Du L, Qiu H, Zhao G, Wang L, Zhou Y, et al. A recombinant protein containing highly conserved hemagglutinin residues 81\u2013122 of influenza H5N1 induces strong humoral and mucosal immune responses. Biosci Trends. 2013 [cited 2025 Sept 10]. Available from: http:\/\/www.biosciencetrends.com\/getabstract.php?id=679."},{"issue":"2","key":"12634_CR107","doi-asserted-by":"publisher","first-page":"326","DOI":"10.3390\/vaccines11020326","volume":"11","author":"AV Kudriavtsev","year":"2023","unstructured":"Kudriavtsev AV, Vakhrusheva AV, Kryuchkov NA, Frolova ME, Blagodatskikh KA, Ivanishin TV, et al. Safety and immunogenicity of betuvax-CoV-2, an RBD-Fc-based SARS-CoV-2 recombinant vaccine: preliminary results of the first-in-human, randomized, double-blind, placebo-controlled phase I\/II clinical trial. Vaccines. 2023;11(2):326.","journal-title":"Vaccines"},{"issue":"4","key":"12634_CR108","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1038\/s41423-021-00658-z","volume":"18","author":"S Sun","year":"2021","unstructured":"Sun S, He L, Zhao Z, Gu H, Fang X, Wang T, et al. Recombinant vaccine containing an RBD-Fc fusion induced protection against SARS-CoV-2 in nonhuman primates and mice. Cell Mol Immunol. 2021;18(4):1070\u201373.","journal-title":"Cell Mol Immunol"},{"key":"12634_CR109","doi-asserted-by":"publisher","first-page":"100444","DOI":"10.1016\/j.jvacx.2024.100444","volume":"16","author":"Y Sun","year":"2024","unstructured":"Sun Y, Li Q, Luo Y, Zhu H, Xu F, Lu H, et al. Development of an RBD-Fc fusion vaccine for COVID-19. Vaccine X. 2024;16:100444.","journal-title":"Vaccine X"},{"issue":"1","key":"12634_CR110","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41541-025-01155-4","volume":"10","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Wu Y, Zhang MQ, Rao H, Zhang Z, He X, et al. An RBD-Fc mucosal vaccine provides variant-proof protection against SARS-CoV-2 in mice and hamsters. Npj Vaccines. 2025;10(1):100.","journal-title":"Npj Vaccines"},{"issue":"7","key":"12634_CR111","doi-asserted-by":"publisher","first-page":"e0288486","DOI":"10.1371\/journal.pone.0288486","volume":"18","author":"S Laotee","year":"2023","unstructured":"Laotee S, Duangkaew M, Jivapetthai A, Tharakhet K, Kaewpang P, Prompetchara E, et al. CHO-produced RBD-Fc subunit vaccines with alternative adjuvants generate immune responses against SARS-CoV-2. PLoS One. 2023;18(7):e0288486.","journal-title":"PLoS One"},{"issue":"4","key":"12634_CR112","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1021\/acs.analchem.0c03173","volume":"93","author":"M Sanda","year":"2021","unstructured":"Sanda M, Morrison L, Goldman R. N- and O-glycosylation of the SARS-CoV-2 spike protein. Anal Chem. 2021;93(4):2003\u201309.","journal-title":"Anal Chem"},{"issue":"10","key":"12634_CR113","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1021\/acscentsci.0c01056","volume":"6","author":"L Casalino","year":"2020","unstructured":"Casalino L, Gaieb Z, Goldsmith JA, Hjorth CK, Dommer AC, Harbison AM, et al. Beyond shielding: the roles of Glycans in the SARS-CoV-2 spike protein. ACS Cent Sci. 2020;6(10):1722\u201334.","journal-title":"ACS Cent Sci"},{"key":"12634_CR114","doi-asserted-by":"crossref","unstructured":"Zhao X, Chen H, Wang H. Glycans of SARS-CoV-2 spike protein in virus infection and antibody production. Front Mol Biosci. 2021;8. https:\/\/www.frontiersin.org\/journals\/molecular-biosciences\/articles\/10.3389\/fmolb.2021.629873\/full.","DOI":"10.3389\/fmolb.2021.629873"},{"issue":"1","key":"12634_CR115","doi-asserted-by":"publisher","first-page":"14991","DOI":"10.1038\/s41598-020-71748-7","volume":"10","author":"OC Grant","year":"2020","unstructured":"Grant OC, Montgomery D, Ito K, Woods RJ. Analysis of the SARS-CoV-2 spike protein glycan shield reveals implications for immune recognition. Sci Rep. 2020;10(1):14991.","journal-title":"Sci Rep"},{"issue":"4","key":"12634_CR116","doi-asserted-by":"publisher","first-page":"589","DOI":"10.3390\/vaccines8040589","volume":"8","author":"R Correia","year":"2020","unstructured":"Correia R, Fernandes B, Alves PM, Carrondo MJT, Rold\u00e3o A. Improving influenza HA-Vlps production in insect high five cells via adaptive laboratory evolution. Vaccines. 2020;8(4):589.","journal-title":"Vaccines"},{"issue":"6","key":"12634_CR117","doi-asserted-by":"publisher","first-page":"438","DOI":"10.4161\/bioe.24514","volume":"4","author":"H Yamaji","year":"2013","unstructured":"Yamaji H, Konishi E. Production of Japanese encephalitis virus-like particles in insect cells. Bioengineered. 2013;4(6):438\u201342.","journal-title":"Bioengineered"},{"issue":"3","key":"12634_CR118","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s12250-018-0030-5","volume":"33","author":"S Dai","year":"2018","unstructured":"Dai S, Zhang T, Zhang Y, Wang H, Deng F. Zika virus baculovirus-expressed virus-like particles induce neutralizing antibodies in mice. Virol Sin. 2018;33(3):213\u201326.","journal-title":"Virol Sin"},{"issue":"1","key":"12634_CR119","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s43856-025-00830-w","volume":"5","author":"TM Renner","year":"2025","unstructured":"Renner TM, Stuible M, Rossotti MA, Rohani N, Cepero-Donates Y, Sauvageau J, et al. Modifying the glycosylation profile of SARS-CoV-2 spike-based subunit vaccines alters focusing of the humoral immune response in a mouse model. Commun Med. 2025;5(1):111.","journal-title":"Commun Med"},{"issue":"1","key":"12634_CR120","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41541-021-00321-8","volume":"6","author":"Q Jia","year":"2021","unstructured":"Jia Q, Bielefeldt-Ohmann H, Maison RM, Masle\u0161a-Gali\u0107 S, Cooper SK, Bowen RA, et al. Replicating bacterium-vectored vaccine expressing SARS-CoV-2 membrane and nucleocapsid proteins protects against severe COVID-19-like disease in hamsters. Npj Vaccines. 2021;6(1):47.","journal-title":"Npj Vaccines"},{"key":"12634_CR121","doi-asserted-by":"crossref","unstructured":"Thura M, En Sng JX, Ang KH, Li J, Gupta A, Hong JM, et al. Targeting intra-viral conserved nucleocapsid (N) proteins as novel vaccines against SARS-CoVs. Biosci Rep. 2021;41(9).","DOI":"10.1042\/BSR20211491"},{"issue":"2","key":"12634_CR122","doi-asserted-by":"publisher","first-page":"376","DOI":"10.4049\/jimmunol.2100421","volume":"207","author":"WE Matchett","year":"2021","unstructured":"Matchett WE, Joag V, Stolley JM, Shepherd FK, Quarnstrom CF, Mickelson CK, et al. Cutting edge: nucleocapsid vaccine elicits spike-independent SARS-CoV-2 protective immunity. J Immunol. 2021;207(2):376\u201379.","journal-title":"J Immunol"},{"key":"12634_CR123","doi-asserted-by":"publisher","first-page":"1188605","DOI":"10.3389\/fimmu.2023.1188605","volume":"14","author":"C Primard","year":"2023","unstructured":"Primard C, Monch\u00e2tre-Leroy E, Del Campo J, Valsesia S, Nikly E, Chevandier M, et al. OVX033, a nucleocapsid-based vaccine candidate, provides broad-spectrum protection against SARS-CoV-2 variants in a hamster challenge model. Front Immunol. 2023;14:1188605.","journal-title":"Front Immunol"},{"issue":"11","key":"12634_CR124","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1016\/j.cell.2023.04.007","volume":"186","author":"CM Arieta","year":"2023","unstructured":"Arieta CM, Xie YJ, Rothenberg DA, Diao H, Harjanto D, Meda S, et al. The T-cell-directed vaccine BNT162b4 encoding conserved non-spike antigens protects animals from severe SARS-CoV-2 infection. Cell. 2023;186(11):2392\u2013409.e21.","journal-title":"Cell"},{"key":"12634_CR125","doi-asserted-by":"publisher","first-page":"104062","DOI":"10.1016\/j.ebiom.2022.104062","volume":"80","author":"S Col\u00e9on","year":"2022","unstructured":"Col\u00e9on S, Wiedemann A, Sur\u00e9naud M, Lacabaratz C, Hue S, Prague M, et al. Design, immunogenicity, and efficacy of a pan-sarbecovirus dendritic-cell targeting vaccine. eBiomedicine. 2022;80:104062.","journal-title":"eBiomedicine"},{"issue":"5","key":"12634_CR126","doi-asserted-by":"publisher","first-page":"106288","DOI":"10.1016\/j.jinf.2024.106288","volume":"89","author":"SO Rabdano","year":"2024","unstructured":"Rabdano SO, Ruzanova EA, Vertyachikh AE, Teplykh VA, Emelyanova AB, Rudakov GO, et al. N-protein vaccine is effective against COVID-19: phase 3, randomized, double-blind, placebo-controlled clinical trial. J Infect. 2024;89(5):106288.","journal-title":"J Infect"},{"issue":"1","key":"12634_CR127","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41541-022-00436-6","volume":"7","author":"F Chiuppesi","year":"2022","unstructured":"Chiuppesi F, Nguyen VH, Park Y, Contreras H, Karpinski V, Faircloth K, et al. Synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates. Npj Vaccines. 2022;7(1):7.","journal-title":"Npj Vaccines"},{"issue":"1","key":"12634_CR128","doi-asserted-by":"publisher","first-page":"14917","DOI":"10.1038\/s41598-021-94364-5","volume":"11","author":"A Rice","year":"2021","unstructured":"Rice A, Verma M, Shin A, Zakin L, Sieling P, Tanaka S, et al. Intranasal plus subcutaneous prime vaccination with a dual antigen COVID-19 vaccine elicits T-cell and antibody responses in mice. Sci Rep. 2021;11(1):14917.","journal-title":"Sci Rep"},{"key":"12634_CR129","doi-asserted-by":"crossref","unstructured":"Huang Y, Chen J, Chen S, Huang C, Li B, Li J, et al. Molecular characterization of SARS-CoV-2 nucleocapsid protein. Front Cell Infect Microbiol. 2024;14. https:\/\/www.frontiersin.org\/journals\/cellular-and-infection-microbiology\/articles\/10.3389\/fcimb.2024.1415885\/full.","DOI":"10.3389\/fcimb.2024.1415885"},{"issue":"2","key":"12634_CR130","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41590-021-01122-w","volume":"23","author":"P Moss","year":"2022","unstructured":"Moss P. The T cell immune response against SARS-CoV-2. Nat Immunol. 2022;23(2):186\u201393.","journal-title":"Nat Immunol"},{"issue":"7","key":"12634_CR131","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","volume":"181","author":"A Grifoni","year":"2020","unstructured":"Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181(7):1489\u2013501.e15.","journal-title":"Cell"},{"issue":"1","key":"12634_CR132","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1080\/22221751.2020.1855945","volume":"9","author":"XY Zhang","year":"2020","unstructured":"Zhang XY, Guo J, Wan X, Zhou JG, Jin WP, Lu J, et al. Biochemical and antigenic characterization of the structural proteins and their post-translational modifications in purified SARS-CoV-2 virions of an inactivated vaccine candidate. Emerg Microbes Infect. 2020;9(1):2653\u201362.","journal-title":"Emerg Microbes Infect"},{"issue":"9","key":"12634_CR133","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.3390\/v14091938","volume":"14","author":"S Yu","year":"2022","unstructured":"Yu S, Wei Y, Liang H, Ji W, Chang Z, Xie S, et al. Comparison of physical and biochemical characterizations of SARS-CoV-2 inactivated by different treatments. Viruses. 2022;14(9):1938.","journal-title":"Viruses"},{"key":"12634_CR134","doi-asserted-by":"crossref","unstructured":"Lopez-Munoz AD, Kosik I, Holly J, Yewdell JW. Cell surface SARS-CoV-2 nucleocapsid protein modulates innate and adaptive immunity. Sci Adv. 2022;8(31).","DOI":"10.1126\/sciadv.abp9770"},{"key":"12634_CR135","doi-asserted-by":"crossref","unstructured":"Fielding CA, Sabberwal P, Williamson JC, Greenwood EJD, Crozier TWM, Zelek W, et al. SARS-CoV-2 host-shutoff impacts innate NK cell functions, but antibody-dependent NK activity is strongly activated through non-spike antibodies. eLife. 2022;11.","DOI":"10.7554\/eLife.74489"},{"issue":"1","key":"12634_CR136","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41590-021-01084-z","volume":"23","author":"Y Peng","year":"2022","unstructured":"Peng Y, Felce SL, Dong D, Penkava F, Mentzer AJ, Yao X, et al. An immunodominant NP105-113-B*07: 02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease. Nat Immunol. 2022;23(1):50\u201361.","journal-title":"Nat Immunol"},{"issue":"2","key":"12634_CR137","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.virol.2006.03.036","volume":"351","author":"H Peng","year":"2006","unstructured":"Peng H, Tao YL, Yun WL, Li J, Huang J, Qiang LZ, et al. Long-lived memory T lymphocyte responses against SARS coronavirus nucleocapsid protein in SARS-recovered patients. Virology. 2006;351(2):466\u201375.","journal-title":"Virology"},{"issue":"3","key":"12634_CR138","doi-asserted-by":"publisher","first-page":"e0247640","DOI":"10.1371\/journal.pone.0247640","volume":"16","author":"FY Tso","year":"2021","unstructured":"Tso FY, Lidenge SJ, Poppe LK, Pe\u00f1a PB, Privatt SR, Bennett SJ, et al. Presence of antibody-dependent cellular cytotoxicity (ADCC) against SARS-CoV-2 in COVID-19 plasma. PLoS One. 2021;16(3):e0247640.","journal-title":"PLoS One"},{"issue":"8","key":"12634_CR139","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1002\/eji.202149470","volume":"52","author":"K Hagemann","year":"2022","unstructured":"Hagemann K, Riecken K, Jung JM, Hildebrandt H, Menzel S, Bunders MJ, et al. Natural killer cell-mediated ADCC in SARS-CoV-2-infected individuals and vaccine recipients. Eur J Immunol. 2022;52(8):1297\u2013307.","journal-title":"Eur J Immunol"},{"key":"12634_CR140","doi-asserted-by":"crossref","unstructured":"Yu Y, Wang M, Zhang X, Li S, Lu Q, Zeng H, et al. Antibody-dependent cellular cytotoxicity response to SARS-CoV-2 in COVID-19 patients. Signal Transduct Target Ther. 2021;6(1).","DOI":"10.1038\/s41392-021-00759-1"},{"issue":"7821","key":"12634_CR141","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41586-020-2550-z","volume":"584","author":"N Le Bert","year":"2020","unstructured":"Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020;584(7821):457\u201362.","journal-title":"Nature"},{"issue":"3","key":"12634_CR142","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.4049\/jimmunol.173.3.1978","volume":"173","author":"KB Renegar","year":"2004","unstructured":"Renegar KB, Small PA, Boykins LG, Wright PF. Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. J Immunol. 2004;173(3):1978\u201386.","journal-title":"J Immunol"},{"issue":"1","key":"12634_CR143","doi-asserted-by":"publisher","first-page":"6871","DOI":"10.1038\/s41467-021-27063-4","volume":"12","author":"D Lapuente","year":"2021","unstructured":"Lapuente D, Fuchs J, Willar J, Vieira Ant\u00e3o A, Eberlein V, Uhlig N, et al. Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization. Nat Commun. 2021;12(1):6871.","journal-title":"Nat Commun"},{"issue":"6","key":"12634_CR144","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41590-025-02156-0","volume":"26","author":"D-i KwonIl","year":"2025","unstructured":"KwonIl D-i, Mao T, Israelow B, Santos Guedes de S\u00e1 K, Dong H, Iwasaki A. Mucosal unadjuvanted booster vaccines elicit local IgA responses by conversion of pre-existing immunity in mice. Nat Immunol. 2025;26(6):908\u201319.","journal-title":"Nat Immunol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-12634-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12634-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12634-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T15:06:02Z","timestamp":1771599962000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-12634-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":144,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["12634"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-12634-x","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]},"assertion":[{"value":"21 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments in this study were carried out following the Finnish Act on the Protection of Animals Used for Scientific or Educational Purposes (497\/2013) and the National Institutes of Health guidelines for laboratory animal care. Procedures were approved by the Regional State Administrative Agency, Pirkanmaa, Finland (decision number ESAVI\/1408\/2021). All animal reporting was conducted in accordance with ARRIVE guidelines. All efforts were made to minimize animal suffering and to reduce the number of animals used. The welfare of the animals was monitored throughout the experiment. Separate ethics committee or IRB approval for animal work is not applicable under Finnish regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"MMH, SG and HL are inventors in a pending patent application FI 20253474 (Immunogenic composition and uses thereof). Based on the Act on the Right in Inventions in Finland, all authors employed by Tampere University have given all rights to the University and, thus, no competing interests exist. RAN, MAR and AP developed the wuRBD-mFc-8his antigen, and they own equity in Nordic SARS Response AB that holds sole ownership and commercialization rights of the wuRBD-mFc-8his cDNA (GenBank ID: PP599180.1) and its derivates used in this study. The remaining authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"430"}}